miRNAs as biomarkers in Lyme Disease: a review
Lyme disease, miRNA, Biomarker, Borrelia burgdorferi, Lyme Arthritis, Lyme Carditis, Neuroborreliosis.
Lyme disease, caused by bacteria of the Borrelia burgdorferi species and transmitted by ticks
of the Ixodes genus, is the most common tick-borne infection in the United States and Europe.
The disease manifests in three stages: early localized (erythema migrans), early disseminated
(flu-like symptoms, neurological and cardiac abnormalities), and late disseminated (arthritis
and neurological deficits). Early diagnosis is challenging, requiring further development of
diagnostic tests. miRNAs, small RNA molecules that regulate gene expression, are emerging
as potential biomarkers and therapeutic targets due to their stability and ability to reflect
pathological states, including bacterial infections such as Lyme disease. Studies indicate that
exosomal miRNAs play a crucial role in cellular communication and the regulation of
pathophysiological processes, highlighting their importance in inflammatory response and
immunity during infections and conditions associated with Lyme disease. This review aimed
to identify potential miRNA biomarkers in Lyme disease. The research was conducted in the
PubMed, Embase, ScienceDirect, Web of Science, and LILACS public databases using the
following search terms: "Lyme Disease" OR "Borrelia burgdorferi" OR "B. burgdorferi" OR
"Lyme Borreliosis" OR "Lyme Arthritis" OR "Lyme Carditis" AND "MicroRNA" OR "miRNA"
OR "miRNAs" OR "miR". miR-146a-5p plays a key role in the negative regulation of the
inflammatory response, indicating that this miRNA may be a relevant biomarker for monitoring
inflammation and pathological processes in the dermal manifestation of the disease and Lyme
arthritis. miR-155 plays a crucial role in regulating the inflammatory response in Lyme carditis,
while miR-145 and miR-146b are involved in microglial activation and inflammation, making
them promising biomarkers and therapeutic targets for Lyme disease.